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Melatonin has many different roles in the human body, including its importance 
in circadian rhythms, sleep physiology, mental status, reproduction, tumour de-
velopment, ageing, and many other physiologic processes. Although there are 
more than hundreds of studies on effects of melatonin in several tissues, its effects 
on peripheral nerve has been documented in a limited number of studies. This 
paper focused to review the available literature in terms of several actions and 
effects of melatonin (beneficial or toxic effects) on well-known peripheral nerve 
injury models. (Folia Morphol 2015; 74, 3: 283–289)
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MELATONIN AND ITS  
PHYSIOLOGIC ACTIONS
Historical background
Melatonin (also known as N-acetyl-5-methoxy-
tryptamine) (Fig. 1) is a hormone and is first identified 
in bovine pineal extracts. This hormone lightens the 
colour of frog melanocytes by its ability to aggregate 
melanin granules either after injection into the frog 
or after in vitro incubation with pieces of frog skin 
[5, 27]. Its melanocyte-lightening property is more 
than ten thousand times greater than that of nora-
drenalin [27]. 
Melatonin was first defined as the hormone that 
mediates the annual fluctuations in reproductive com-
petence in seasonally breeding animals, as well as in-
fluencing numerous aspects of circadian biology [39].
Biosynthesis of melatonin 
Melatonin is a highly lipophilic molecule, as well 
as having hydrophilic properties; rather than being 
stored in a secretory organ, upon biosynthesis it is 
released into bloodstream through capillaries [29]. 
Tryptophan plays a key role in biosynthesis of me-
latonin. Tryptophan is first converted by tryptophan 
hydroxylase to 5-hydroxytryptophan, which is decar- 
boxylated to serotonin. Two enzymes (serotonin 
N-acetyltransferase and hydroxyindole O-methyltransfe- 
rase) that are largely confined to the pineal gland 
catalyse the synthesis of melatonin from serotonin [5]. 
As the synthesis of melatonin increases, the hormone 
enters the bloodstream through passive diffusion. 
Melatonin synthesis and release are stimulated by 
darkness and inhibited by light (Fig. 1). In humans, 
melatonin secretion increases soon after the onset of 
darkness, peaks in the middle of the night (between 
2 and 4 a.m.), and gradually falls during the second 
half of the night. Serum melatonin concentrations 
vary considerably according to age [5].
Physiologic effects of melatonin
Both in vitro [36, 37, 40] and in vivo studies [53] 
have shown that the neurohormone melatonin is a more 
potent free radical scavenger of the highly toxic hydroxyl 
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and peroxyl radicals than some other known compo-
unds [39]. Melatonin seems to be more effective than 
other known antioxidants (e.g., mannitol, glutathione, 
and vitamin E) in protecting against oxidative dama-
ge [5]. Therefore, melatonin may provide protection 
against oxidative damage in some diseases that cause 
degenerative or proliferative changes. However, these 
antioxidant effects require concentrations of melatonin 
that are much higher than peak nighttime serum con-
centrations [5]. Damage of the peripheral nerve also 
causes the production of free oxygen radicals [2]. When 
damage occurs to a peripheral nerve, both ischaemic 
and inflammatory processes begin. As a consequence of 
this process, free oxygen radicals and many toxic agents 
accumulate around the site of injury [2]. 
The neurohormone melatonin is a powerful antio-
xidant in vivo [39]. It prevents the toxicity of singlet 
oxygen and stimulates the antioxidative enzyme, glu-
tathione peroxidase [39]. Glutathione peroxidase and, as 
a consequence, glutathione reductase activities follow 
the rhythm of melatonin. Involvement of melatonin in 
the control of redox processes has also been addressed 
by its high-affinity binding to cytosolic quinone reducta-
se 2, previously believed to be a melatonin receptor [18]. 
Considering varied and potent antioxidant capabi-
lity of melatonin, it has been reported that melatonin 
is an essential element of the antioxidant defence 
system of organisms [39]. Direct actions of melatonin 
in oxidative status may have important clinical impli-
cations considering the harmful role of free radicals 
in many disease processes [39]. 
Melatonin has many different roles in the human 
body, including its importance in circadian rhythms, 
sleep physiology, mental status, reproduction, tumour 
development, ageing, and many other physiologic 
processes [2]. Besides its well-known regulatory role 
on circadian rhythm, melatonin has other biological 
functions and a distinct metabolism in various cell 
types and peripheral tissues [28]. 
MELATONIN IN TRAUMATIC INJURIES 
OF PERIPHERAL NERVE
Effect of melatonin treatment to  
reduce scar formation
Advances in microsurgical instrumentation and gre-
at progress in nerve repair have provided the technical 
impetus for nerve reconstruction. However, the clinical 
Figure 1. Biosynthesis of melatonin.
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in vitro and in vivo conditions following peripheral 
nerve injury and improved nerve regeneration [7]. 
The increased expression of Schwann cells induced 
by melatonin was clearly expressed by cell counting 
and the proliferative assay in spontaneous immor-
talised rat Schwann cell line derived from long-term 
culture of rat primary Schwann cells (RSC 96 cells) as 
well as by quantitative bromodeoxyuridine (BrdU) 
immunostaining and S-100β immunoexpressions in 
the lesioned nerves [7]. 
The proliferative effect of melatonin on Schwann 
cells has further been demonstrated to be mediated 
by MT1 receptor-dependent phosphorylation of ex-
tracellular signal-regulated kinases (ERK1/2) pathway 
[7, 28]. Increased ERK1/2 activation would transmit 
signals into perikarya of the nerve for transcriptio-
nal regulation of genes related to Schwann cell dif-
ferentiation and proliferation [54, 62]. It has been 
suggested that ERK activation is important in the 
establishment of a regeneration-promoting extracel-
lular environment in proximal and distal stumps of 
transected nerves [1, 50]. Seo et al. [49] also reported 
that increased ERK1/2 activation would contribute to 
Schwann cell proliferation and play an important role 
in sciatic nerve regeneration. 
Effect of melatonin on re-innervation  
of the motor end plates
It is believed that the major reason for the poor 
functional recovery after a peripheral nerve lesion 
is collateral branching and regrowth of axons to in-
correct muscles. It has been suggested that correct 
re-innervation of the neuromuscular junctions, rather 
than collateral axonal branching at the lesion site, 
may be the critical limiting factor for recovery of fun-
ction after peripheral nerve injury [17]. Chang et al. [7] 
recently demonstrated that re-innervated motor end 
plates (as labelled by PGP 9.5 and a-bungarotoxin) 
following peripheral nerve injury was much higher 
in the animals receiving melatonin treatment when 
compared to that of saline-treated ones.
Effect of melatonin treatment on  
apoptosis and neuronal cell death 
Melatonin is able to reduce not only apoptotic cell 
death in the central nervous system [38] but also the 
death of rat motoneurons induced by sciatic nerve 
transection in neonatal rats [44]. Rogerio et al. [44] 
reported a significant decrease in motor neuron death 
in the neonatal spinal cord after administration of 
results for nerve repair are usually disappointing, and 
functional recovery is often suboptimal after peripheral 
nerve injury. Scar formation is a challenge for periphe-
ral nerve surgeon. Traditionally, surgeons attempt to 
control collagen scar formation by close approximation 
of corresponding fascicles of the proximal to distal 
stumps [14, 19]. Although excellent coaptation has 
been achieved in matching proximal and distal nerve 
stumps and proper guiding axon regeneration toward 
the original target tissues, full recovery of nerve fun-
ction does not guarantee in every patients [11]. 
A neuroma is a collection of disorganised nerve fi-
bres sprouted from proximal stump of the injured nerve 
emanating from an interruption of axonal continuity. 
Excessive collagen formation can create a mechanical 
barrier to axonal regeneration, and the resulting scar 
formation can hinder axonal regrowth [21, 24, 31]. 
A variety of techniques have been proposed to decrease 
the neuroma formation characterised by accumulation 
of connective tissue at the lesion site [15, 19, 31]. 
It has been reported that recovery of peripheral 
nerve depends on a balance between Schwann cell 
regeneration and scar tissue formation [10, 21]. Pre-
vious studies have shown that exogenous melatonin 
administration can reduce scar formation in nerve 
stump and can prevent collagen production in the 
granulation tissue in the peripheral nerve of the pi-
nealectomised animals [12, 33, 56]. 
Weichselbaum et al. [60] demonstrated that in pi-
nealectomised rats, wound healing is slower than in 
controls, and this effect can be reversed by treatment 
with melatonin. Cunnane et al. [8] and Drobnik and 
Dabrowski. [12] reported that tissue collagen content 
in pinealectomised rats was found to be elevated due 
to low melatonin level. A variety of growth factors may 
play role in collagen synthesis. The immunohistochemi-
cal profile of transforming growth factor (TGF-b1) and 
basic fibroblast growth factor (bFGF) in the lesion site 
of the sciatic nerve, after pinealectomy and exogenous 
melatonin administration, was investigated by Turgut et 
al. [55]. They reported that TGF-b1 and bFGF immunore-
activity was most intense in the epineurium in animals 
that had undergone pinealectomy, while negative or 
weakly positive immunoreactivity was observed in ani-
mals in control and melatonin-treated groups [55].  
Proliferative effects of melatonin  
on Schwann cells
A recent study demonstrated that melatonin signi-
ficantly promoted Schwann cell proliferation in both 
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melatonin at doses of 1, 5, 10, and 50 mg/kg before 
and at 7 time intervals after sciatic nerve cut injury. 
In their study, neuronal survival rate was higher in 
those animals treated with lower doses of melatonin 
rather than higher doses.
Therapeutic dose of melatonin
In human studies, delivered doses of melatonin 
varied in a very large range, from 0.1 mg to 2000 mg [2]. 
After intravenous administration melatonin is 
rapidly distributed and eliminated [20], while bioavai- 
lability of orally administered melatonin varies widely [5]. 
Melatonin dosages over 0.5 mg are accepted as phar-
macologically therapeutic [5, 45]. 
It has been reported that plasma melatonin levels 
reached a steady-state after 60 min and 120 min after 
melatonin administration [30]. In another study, the 
maximal mean serum melatonin value reached 20 min 
after a single subcutaneous injection of melatonin in 
hamsters [57]. Moreover, peak serum melatonin levels 
were observed after 60–150 min and remained stable 
for approximately 90 min after administration of cry-
stalline melatonin to 5 young male volunteers [59]. 
Because there is no consensus on the therapeutic 
dose of melatonin, different doses have been fre-
quently used in animal studies. Shokouhi et al. [51] 
investigated the neuroprotective effects of melatonin 
on neural fibre damage and lipid peroxidation after 
a blunt sciatic nerve trauma, comparing the effects 
of low dose (10 mg/kg) and high dose (50 mg/kg) of 
melatonin. According to their results, low-dose me-
latonin (10 mg/kg) reduced trauma-induced myelin 
breakdown and axonal changes in the sciatic nerve. 
However, high-dose melatonin (50 mg/kg) almost 
entirely neutralised any ultrastructural changes. The-
refore, they suggested that melatonin has a potent 
neuroprotective effect at a dose of 50 mg/kg and it 
can preserve peripheral neural fibres from lipid pero-
xidative damage after blunt sciatic nerve trauma [51]. 
Peripheral nerve functions in the ovariectomised rats 
receiving melatonin (5 or 20 mg/kg) daily for either 
2 or 6 weeks have also been examined [13].  
Rogerio et al. [44] compared 1, 5, 10, and 50 mg/kg 
melatonin doses on motor neuron death in the 
neonatal spinal cord after sciatic nerve cut injury. 
Very low doses of melatonin have also been stu-
died. Cunnane et al. [8] administered melatonin 
(30 µg/100 g body weight) after surgical pinealec-
tomy procedure. They found low collagen content 
in the lesion site, demonstrating the opposite effect 
of melatonin application on elevated collagen level 
caused by pineal gland removal [12]. Atik et al. [2] 
reported that beneficial effects of melatonin cannot 
be achieved at physiologic doses. Therefore they 
proposed higher doses and a longer duration of 
administration should be planned in experimental 
paradigms [2]. In line of Atik et al. [2], a potent 
neuroprotective effect to preserve peripheral neural 
fibres from lipid peroxidative damage after blunt 
trauma achieved by Shokouhi et al. [51] especially 
at a dose of 50 mg/kg. In our previous studies we 
also administered 50 mg/kg melatonin after sciatic 
nerve injury [22, 23]. 
Effect of disruption of melatonin treatment
Melatonin concentrations in the body are typi-
cally lower during the day and reach to maximal 
levels at night in the dark [59]. In a recent study, we 
studied the effect of exogenous melatonin treatment 
on cut or crush injuries of the sciatic nerve and 
demonstrated that melatonin treatment had signi-
ficant beneficial effect on sciatic nerve injury [22]. 
This treatment was performed in the light period 
and its effects were studied on cut and crush injury 
models of the sciatic nerve. In another recent study 
we re-addressed the beneficial effect of melatonin 
treatment and tried to improve this beneficial effect 
on cut injury by disruption of the circadian rhythm 
induced by light-at-night [23]. Although we used the 
same dose of melatonin as used in previous study 
[22] and found beneficial effect on sciatic nerve 
injury evaluated by functional, ultrastructural, bio-
chemical tests; circadian rhythm disruption induced 
by light-at-night surprisingly did not demonstrate 
the same effect as expected [23]. We think that 
further studies need to be conducted to elucidate 
mechanism of this unexpected effect of melatonin 
in disrupted circadian rhythm.
Combination of melatonin with other substances
Kaplan et al. [21] studied postoperative intraperi-
toneal melatonin administration after intraoperative 
autologous platelet gel application in the collagen 
nerve conduit. They found that combination of me-
latonin with autologous platelet gel enrichment and 
the use of melatonin alone did not improve nerve 
regeneration. In the light of this negative effect, they 
suggested that effects of melatonin on nerve rege-
neration may not be because of the inhibition of 
collagen formation [21].
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The effect of melatonin treatment  
in cut and crush injuries
The effect of the melatonin treatment has frequ-
ently been studied in neurotmesis (cut injury) model. 
However, in a previous study we studied its effect 
on axonotmesis (crush injury) and neurotmesis (cut 
injury) models of sciatic nerve [22]. We found that rats 
treated with melatonin demonstrated better structu-
ral preservation of the myelin sheaths compared to 
the vehicle-treated animals. The biochemical analysis 
also confirmed the beneficial effects of melatonin 
displaying lower lipid peroxidation and higher supero-
xide dismutase, catalase, and glutathione peroxidase 
activities in sciatic nerve samples in comparison to 
vehicle-treated animals. 
MELATONIN IN OTHER TYPES  
OF PERIPHERAL NERVE INJURIES
Penetrating injury, crush, traction, ischaemia, and 
less common mechanisms such as thermal, electric 
shock, radiation, percussion, and vibration may be 
one of the aetiological factors of peripheral nerve 
injury [41, 42]. Ischaemia–reperfusion (I/R) is a prob-
lem that occurs in a variety of clinical conditions and 
leads to endoneurial oedema, segmental demyelisa-
tion, axonal degeneration, conduction failure, and 
multifocal or diffuse loss of nerve fibres [3, 32, 33]. 
Reperfusion after ischaemic insult of the tissue may 
elevate the production of various reactive oxygen 
species which damage a variety of molecules leading 
to cellular dysfunctions [16]. 
Several studies have investigated the effect of 
melatonin on I/R-injury. It has been well documented 
that melatonin provides protection against I/R injury 
of the liver [48], heart [25, 46], intestine [9], and brain 
[34, 52, 58]. However, effect of melatonin on I/R injury 
in the peripheral nerves has only been studied by 
Sayan et al. [47]. They demonstrated that melatonin 
treatment prevented increase in the malondialdehyde 
levels after I/R injury of the sciatic nerve. Melatonin 
also restrained an I/R induced decrease in the supero-
xide dismutase enzyme activity. Moreover, they found 
that pretreatment with melatonin resulted in fewer 
morphologic alterations in terms of the ultrastructural 
features of the sciatic nerve. 
TOXICITY AFTER MELATONIN  
ADMINISTRATION
Although there are numerous studies that men-
tion beneficial effects of melatonin treatment on 
peripheral nerve pathologies, there are some exper-
imental and clinical studies that report a toxic effect 
of melatonin on peripheral nerves [33]. Lehman and 
Johnson [26] mentioned potential drug interaction of 
melatonin with Zoloft (an antidepressant drug also 
known as Sertraline). Combined use of melatonin, Zo-
loft, and a high-protein diet resulted in a melatonin/ 
/dopamine imbalance in the retina, manifesting as 
a toxic optic neuropathy [26]. 
Melatonin is known to interact with neuronal 
microtubules [6] and competes with microtubule-
-disruptive drugs like Vinblastine and Colchicine [4, 
61]. Piezzi and Cavicchia [35] studied morphological 
changes in microtubules of toad sciatic nerve under 
melatonin administration and they found that the 
majority of microtubules of sciatic nerve of both 
control and melatonin-treated groups showed di-
sintegration after 2 h of cooling. Thereafter, while 
microtubules were reformed in the control group 
nerves, the disorganisation of microtubules persisted 
in the sciatic nerves treated with melatonin when 
room temperature was restored (in toad sciatic nerve, 
microtubules are thermodependent). Their integrity, 
which is disrupted by low temperature, is restored 
when the nerves are placed at room temperature [43]. 
CONCLUSION AND  
FUTURE PERSPECTIVE
Beneficial effects of melatonin treatment on neu-
roma formation at the lesion site and on recovery 
of function in peripheral nerve seem a particularly 
attractive treatment option in clinic. Although there 
are few studies reporting toxic effect of melatonin 
administration, there are great numbers of studies on 
beneficial effects of melatonin on peripheral nerves. 
We think that further studies should be carried on 
peripheral nerves to clearly refine beneficial or toxic 
effects of melatonin administration in low, therapeu-
tic and higher doses.
Although different agents have been studied on their 
effect on peripheral nerve regeneration, novel drugs for 
peripheral nerve injury will also be required. We think 
that detailed studies will clarify therapeutic effects of 
melatonin and the use of melatonin as a neuroprotective 
agent could be possible in the clinical practice
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